Compounds > 2-pyridylcarboxaldehyde isonicotinoylhydrazone
Page last updated: 2024-11-11

2-pyridylcarboxaldehyde isonicotinoylhydrazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-pyridylcarboxaldehyde isonicotinoylhydrazone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5469565
CHEMBL ID401362
SCHEMBL ID13826736
MeSH IDM0357498

Synonyms (25)

Synonym
F0267-4515
(e)-n'-(pyridin-2-ylmethylene)isonicotinohydrazide
inh 2pyrcho der
n-[(e)-2-pyridylmethyleneamino]pyridine-4-carboxamide
nsc690252
2-pyridinecarboxaldehyde isonicotinoyl hydrazone
nsc-76233
15017-32-0
nsc76233
STK106708
n'-[(e)-pyridin-2-ylmethylidene]pyridine-4-carbohydrazide
2-pyridylcarboxaldehyde isonicotinoylhydrazone
MLS001201169
n'-[(1e)-pyridin-2-ylmethylene]isonicotinohydrazide
smr000564089
CHEMBL401362
AKOS001568478
n-[(e)-pyridin-2-ylmethylideneamino]pyridine-4-carboxamide
SCHEMBL13826736
DTXSID10420210
(e)-n'-(pyridin-2-ylmethylene) isonicotinohydrazide
n'-[(e)-(pyridin-2-yl)methylidene]pyridine-4-carbohydrazide
SR-01000143050-1
sr-01000143050
2-pyridylcarboxaldehyde isonicotinoyl hydrazone

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Iron (Fe) chelation therapy was initially designed to alleviate the toxic effects of excess Fe evident in Fe-overload diseases."( Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
Kalinowski, DS; Richardson, DR, 2007)		0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency70.79460.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency23.93410.007215.758889.3584AID588342
phosphopantetheinyl transferaseBacillus subtilisPotency19.95260.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency16.46190.004110.890331.5287AID504466; AID504467
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency1.12200.707912.194339.8107AID720542
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency15.84890.707936.904389.1251AID504333
P53Homo sapiens (human)Potency2.51190.07319.685831.6228AID504706
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.79430.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency2.51190.01262.451825.0177AID485313
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.46110.00419.984825.9290AID504444
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency1.58490.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency11.22020.050127.073689.1251AID588590
Guanine nucleotide-binding protein GHomo sapiens (human)Potency12.58931.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1668218Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 30 mins (Rvb = 1.9 +/- 1.2%)2020Bioorganic & medicinal chemistry, 05-15, Volume: 28, Issue:10
Acylhydrazones as isoniazid derivatives with multi-target profiles for the treatment of Alzheimer's disease: Radical scavenging, myeloperoxidase/acetylcholinesterase inhibition and biometal chelation.
AID312544Antiproliferative activity against human SK-MN-C cells by MTT assay2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
AID1668220Inhibition of rat bone marrow myeloperoxidase using H2O2 as substrate at 10 uM after 20 mins by TMB based method (Rvb = - 1.4 +/- 12.7%)2020Bioorganic & medicinal chemistry, 05-15, Volume: 28, Issue:10
Acylhydrazones as isoniazid derivatives with multi-target profiles for the treatment of Alzheimer's disease: Radical scavenging, myeloperoxidase/acetylcholinesterase inhibition and biometal chelation.
AID1668222Inhibition of Electrophorus electricus AChE at 100 uM using acetylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition and measured after 10 mins by Ellman's method (Rvb = 7 +/- 7.1%)2020Bioorganic & medicinal chemistry, 05-15, Volume: 28, Issue:10
Acylhydrazones as isoniazid derivatives with multi-target profiles for the treatment of Alzheimer's disease: Radical scavenging, myeloperoxidase/acetylcholinesterase inhibition and biometal chelation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's7 (50.00)29.6817
2010's4 (28.57)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.64 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyridoxal
[no description available]		2.0310hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		2.0410acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.7830carbohydrazideantitubercular agent;
drug allergen
hydrazine
diamine : Any polyamine that contains two amino groups.		2.4220azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
rivastigmine
[no description available]		2.2510carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
quercetin
[no description available]		2.25107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
2-pyridylcarboxaldehyde benzoylhydrazone
2-pyridylcarboxaldehyde benzoylhydrazone: structure in first source		7.4220
3-nitrobenzaldehyde isonicotinoylhydrazone
3-nitrobenzaldehyde isonicotinoylhydrazone: structure in first source		2.2510
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
3-aminopyridine-2-carboxaldehyde thiosemicarbazone: a neuroprotective agent; structure given in first source		2.4420
di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone
[no description available]		2.0410
di-2-pyridyl ketone isonicotinoyl hydrazone
di-2-pyridyl ketone isonicotinoyl hydrazone: a chelating agent; structure in first source		2.0410
salinazid
[no description available]		2.2510aromatic carboxylic acid;
pyridinemonocarboxylic acid
2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone
2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone: structure in first source		2.0410
tju 103
[no description available]		2.2510
pyridoxal isonicotinoyl hydrazone
pyridoxal isonicotinoyl hydrazone: acts as iron chelating agent		2.4420
phthivazide
[no description available]		2.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Iron Overload
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)		03.8640
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Acute Confusional Senile Dementia
[description not available]		02.2510
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.2510